Clarissa Braccia is a Post-Doc at ProMeFa (Proteomics and Metabolomics Facility) in the Center of Omics Sciences at IRCCS Ospedale San Raffaele.  

She got her degree in Medicinal Chemistry and Pharmaceutical Technology at the Università degli Studi di Milano (Milan, Italy) in 2017, with a thesis focused on the analysis of the Panax ginseng root proteome.  

In 2020, she got her PhD in “Drug discovery and nanobiotechnologies” at the Università degli Studi di Genova – Istituto Italiano di Tecnologia (Genoa, Italy). Her PhD project was about discovering new potential targets for cystic fibrosis (CF) treatment by the use of Mass spectrometry-based omics techniques, including the development of ion libraries for data independent acquisition (DIA). She learnt how to exploit omics experiments to provide insights into the changes at molecular level. During her PhD, she had the great opportunity to be hosted by Professor Kathryn Lilley at the University of Cambridge (UK), where she applied the LOPIT-DC technique to a CF in-vitro model (CFBE41o- cells) to detect differences in subcellular protein localization associated with pharmacological treatment.  

In 2021, she started working as a Post-Doc within the WP4 of the European Graphene Flagship at the Analytical Chemistry Lab of the Istituto Italiano di Tecnologia (Genoa, Italy). Her research focused on developing new Mass spectrometry-based methods to identify and quantify both proteins and lipids. These tools were used to study how cells and organs react to exposure to Graphene-related materials, with a particular focus on neurotoxicity. 

In 2022, she joined the ProMeFa (Proteomics and Metabolomics Facility), guided by Dr Annapaola Andolfo. Her current research aims at developing innovative proteomic and metabolomic approaches for different research projects.